

### Summary of fund objective

The Fund is actively managed. The Fund aims to achieve long term capital growth. The Fund seeks to achieve its objective by investing primarily in a concentrated portfolio of Chinese healthcare companies. Such companies will be listed on the Shanghai or Shenzhen Stock Exchanges, traded via Stock Connect (which may include companies listed on the ChiNext Board or the Science and Technology Innovation (STAR) board) as well as those listed or traded elsewhere, included via Qualified foreign investor(s) (QFI). Up to 30% of the NAV of the Fund may be exposed to China-A shares via QFI. For the full objectives and investment policy please consult the current prospectus.

### **Key facts**

Chris Liu
Hong Kong
Managed fund since
December 2020
Share class launch 03 March 2021
<b>Original fund launch</b> 15 December 2020
Legal status
Luxembourg SICAV with UCITS status
Share class currency EUR
Share class type Accumulation
<b>Fund size</b> CNH 892.85 mn
Bloomberg code INHCEZE LX
ISIN code
LU2305833589
Settlement date
Trade Date + 2 Days

### Invesco China Health Care Equity Fund Z (EUR Hgd)-Acc Shares <sup>31 May 2023</sup>

This marketing communication is directed at retail clients in the UK. Investors should read the legal documents prior to investing.


### Investment risks

For complete information on risks, refer to the legal documents. The value of investments and any income will fluctuate (this may partly be the result of exchange rate fluctuations) and investors may not get back the full amount invested. As a large portion of the fund is invested in less developed countries, you should be prepared to accept significantly large fluctuations in the value of the fund. As this fund is invested in a particular country, you should be prepared to accept greater fluctuations in the value of the fund than for a fund with a broader investment mandate. The fund may invest in certain securities listed in China which can involve significant regulatory constraints that may affect the liquidity and/or the investment performance of the fund. The fund invests in a limited number of holdings and is less diversified. This may result in large fluctuations in the value of the fund than for a fund with a broader investment mandate.

### **Fund Strategy**

Our investment strategy combines a deep understanding of key industry drivers and a robust bottom-up stock selection approach. We focus on Chinese healthcare companies with long-term growth potential based on industry leadership and competitive advantages, clear business strategies and transparent corporate governance. Our strategy not only looks at large market leaders but also small and medium sized companies, which have unique competitive advantages in different subsectors. The fund has higher exposure to CROs (Contract Research Organisations) and CDMOs (Contract Manufacturing Organisations), as well as selected exposure to pharmaceutical companies with strong pipelines of innovative drugs.

Past performance does not predict future returns. Data points are as at month end.



Cun	nulative	performance*			
in 0/2			VTD	1 month	1

in %	YTD	1 month	1 year	3 years	Since inception
Fund	-1.28	-5.60	5.07	-	-46.10
Calendar year pe		018 201	.9 20	20 20	2022
Fund		-	-	-	27.10
Standardised rol	ling 12 montl		<b>1Ce*</b> .17 05.18	05.19 05.20	0 05.21 05.22

	05.13	05.14	05.15	05.16	05.17	05.18	05.19	05.20	05.21	05.22
in %	05.14	05.15	05.16	05.17	05.18	05.19	05.20	05.21	05.22	05.23
Fund	-	-	-	-	-	-	-	0.00	-51.74	5.07

The performance data shown does not take account of the commissions and costs incurred on the issue and redemption of units. Returns may increase or decrease as a result of currency fluctuations. The investment concerns the acquisition of units in a fund and not in a given underlying asset.


# Invesco China Health Care Equity Fund Z (EUR Hgd)-Acc Shares

31 May 2023

Top 10 holdings*		(total holdings: 32)	
Holding	Sector	%	
Shenzhen Mindray Bio-Medical Electronics 'A'	Health Care Equipment & Supplies	7.2	
Meinian Onehealth Healthcare 'A'	Health Care Providers & Services	6.4	
Jointown Pharmaceutical 'A'	Health Care Providers & Services	6.2	
Humanwell Healthcare 'A'	Pharmaceuticals	5.5	
Asymchem Laboratories Tianjin 'A'	Pharmaceuticals	5.0	
Hangzhou Tigermed Consulting 'A'	Life Sciences Tools & Services	4.8	
Aier Eye Hospital 'A'	Health Care Providers & Services	4.8	
KPC Pharmaceuticals 'A'	Pharmaceuticals		
China National Accord Medicines 'A'	Health Care Providers & Services	4.0	
Beijing Tongrentang 'A'	Pharmaceuticals	3.9	
Geographical weightings of the fund in %*	Geographical weightings*	Sector weightings*	



### Sector weightings of the fund in %\*



### NAV and fees

Current NAV EUR 5.39
<b>12 month price high</b> EUR 6.21 (05/07/2022)
<b>12 month price low</b> EUR 4.56 (23/09/2022)
Minimum investment <sup>1</sup> EUR 1,000
Entry charge Up to 5.00%
Annual management fee 0.75%
Ongoing charges <sup>2</sup> 1.09%

Average weighted market capitalisation	EUR 11.00 bn
Median market capitalisation	EUR 3.59 bn

in %

93.9

2.7

3.4

Health Care Providers & Services

Health Care Equipment & Supplies

Life Sciences Tools & Services

Consumer Staples Distribution &

Pharmaceuticals

Biotechnology

Retail

Cash

in %

29.7

28.4

14.7

12.7

7.9

3.3

3.4

# Sector weightings ographical weightings

## Financial characteristics\*

China

Cash

Hong Kong

### Important Information

<sup>1</sup>The minimum investment amounts are: USD 1,500 / EUR 1,000 / GBP 1,000 / CHF 1,500 / SEK 10,000. Please contact us or refer to the most up to date Prospectus for details of minimum investment amounts in other currencies. <sup>2</sup>The Ongoing Charges figure includes the annual management fee and other administrative or operating costs. It is a percentage of the value of your investment per year. This is an estimate based on actual costs over the last year.

### This marketing communication is directed at retail clients in the UK. Investors should read the legal documents prior to investing.

Where individuals or the business have expressed opinions, they are based on current market conditions, they may differ from those of other investment professionals and are subject to change without notice. This marketing communication is not an invitation to subscribe for shares in the fund and is by way of information only, it should not be considered financial advice. Persons interested in acquiring the fund should inform themselves as to (i) the legal requirements in the countries of their nationality, residence, ordinary residence or domicile; (ii) any foreign exchange controls and (iii) any relevant tax consequences. This does not constitute an offer or solicitation by anyone in any jurisdiction in which such an offer is not authorised or to any person to whom it is unlawful to make such an offer or solicitation. As with all investments, there are associated risks. This document is by way of information only. Asset management services are provided by Invesco in accordance with appropriate local legislation and regulations. The fund is available only in jurisdictions where its promotion and sale is permitted. Not all share classes of this fund may be available for public sale in all jurisdictions and not all share classes are the same nor do they necessarily suit every investor. Fee structure and minimum investment levels may vary dependent on share class chosen. Please check the most recent version of the fund prospectus in relation to the criteria for the individual share classes and contact your local Invesco office for full details of the fund registration status in your jurisdiction. This is marketing material and not intended as a recommendation to buy or sell any particular asset class, security or strategy. Regulatory requirements that require impartiality of investment/investment strategy recommendations are therefore not applicable nor are any prohibitions to trade before publication. For more information on our funds and the relevant risks, please refer to the share class-specific Key Investor Information Documents, the Annual or Interim Reports, the Prospectus, and constituent documents, available from www.invesco.eu. A summary of investor rights is available in English from www.invescomanagementcompany.lu. The management company may terminate marketing arrangements. Please be advised that the information provided in this document is referring to the Z (EUR Hgd)-Acc Shares exclusively. The Invesco China Health Care Equity Fund is domiciled in Luxembourg.

© 2023 Morningstar. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

Additional information for the UK: Issued by Invesco Management S.A., President Building, 37A Avenue JF Kennedy, L-1855 Luxembourg, regulated by the Commission de Surveillance du Secteur Financier, Luxembourg.

### SFDR (Sustainable Finance Disclosure Regulation)

The Fund complies with Article 8 with respect to the EU's Sustainable Finance Disclosure Regulation\*. As such, the fund promotes, among other characteristics, environmental or social characteristics or a combination of those characteristics. In addition, the companies in which the fund invests follow good governance practices. \*Regulation (EU) 2019/2088 on sustainability – related disclosures in the financial services sector.

### **Exclusion Framework**

The Fund embeds an exclusionary framework to specific activities based on UN Global Compact, severe governmental sanctions, revenue thresholds for certain activities linked to environmental and/or social criteria, as well as ensuring that companies follow good governance practices. The list of activities and their thresholds are listed below:

UN Global Compact	- Non-Compliant
Country sanctions	- Sanctioned investments are prohibited*
Controversial weapons	<ul> <li>0% of revenue including companies involved in the manufacture of nuclear warheads or whole nuclear missiles outside of the Non-Proliferation Treaty (NPT)</li> </ul>
Coal	<ul> <li>Thermal Coal extraction: &gt;=5% of revenue</li> <li>Thermal Coal Power Generation: &gt;=10% of revenue</li> </ul>
Unconventional oil & gas	- >= 5% of revenue on each of the following: Artic oil & gas exploration; Oil sands extraction; Shale energy extraction;
Торассо	<ul> <li>Tobacco Products production: &gt;=5% of revenue</li> <li>Tobacco related products and services: &gt;=5% of revenue</li> </ul>
Others	- Recreational cannabis: >=5% of revenue
Good governance	<ul> <li>Ensure that companies follow good governance practices in the areas of sound management structures, employee relations, remuneration and tax compliance</li> </ul>
Military Contracting	- Military Contracting Overall >=10% - Small Arms Overall >=0%

\*At Invesco we continuously monitor any applicable sanctions, including those imposed by the UN/US/EU and UK. These sanctions may preclude investments in the securities of various governments/regimes/entities and as such will be included in our compliance guidelines and workflows (designed to ensure compliance with such sanctions). The wording of international sanctions is something that we pay particular attention to as there are occasions where sanctions can exist in limited form, for example allowing investments in the secondary market. In addition to sanctions targeting entire countries, there are other thematic regimes, which may focus for example on human rights, cyber attacks, terrorist financing and corruption, which may apply to both individuals and/or entities/corporations.

Any investment decision should take into account all the characteristics of the fund as described in the legal documents. For sustainability related aspects, please refer to: https://www.invescomanagementcompany.lu/lux-manco/literature.

At Invesco we have looked to put in place minimum safeguards across multiple sub-funds of Invesco Funds (as listed above) to allow them to meet Article 8 requirements of the SFDR Regulation as of 2 November 2021. To be classified as a so-called Article 8 product, the sub-funds need to promote, among other things, environmental and/or social characteristics while also ensuring that investee companies follow good governance practices. In order to meet such requirements, it was determined that we would look to exclude certain activities based on certain thresholds, which may be updated from time to time. For further details please refer to the website of the management company at https://www.invescomanagementcompany.lu.

As noted above this is a proprietary framework developed by Invesco in line with Article 8 requirements of the Regulation (EU) 2019/2088 on sustainability. The framework is developed, maintained and monitored by Invesco. In order to assess companies against the noted criteria, Invesco uses a combination of Sustainalytics and ISS (Institutional Shareholder Services) to assess compliance, however, this can be supplemented with other service providers where appropriate. While there is a broad coverage across the various systems, there is no one system that has complete coverage of the entire investment universe. As a result, investment teams will be responsible for conducting an assessment of companies for which data is not available, under the appropriate supervision and oversight of our investment compliance and ESG teams.

### Invesco's Commitment to ESG

Invesco has an investment-led ESG approach. We provide a comprehensive range of ESG-focused capabilities that enable clients to express their values through investing. We also integrate financially material ESG considerations across our investment platform, taking into account critical factors that help us deliver strong outcomes to clients.